Dear US Food & Drug Administration

I am writing to concerning study design and safety information on all new and or ongoing Clinical trials involving either gene therapy or Xenotransplatation. Here are some important points to consider - Docket Number 00N-0989

1. This proposal only brings gene therapy and xenotransplatation in compliance with the same types of information already released to the public by other government Agencies. Because of grave Health risks to the publice - discolusure should include additional information such as physicians, medical Centres, etc - make public all information except trade secrets and patient identification

2. The FDA must assume all sole responsibility for summerizing and distributing information submitted by the research sponser, rather then leave it to the sponsers discretion

3. Because of public Health risk, ethical issues, cost uncertainty, and the inabality to adequately assess other alternatives, all xenotransplantation clinical trials should stop.

Thank you for taking the time to read my letter Act quickly on docket number 00N-0989 as soon as possible. Respond ASAP

C134

00N-0989

C. Bingham
140 Union Avenue
Peekskill, NY 10566

WESTCHESTER NY 105
PM
04 MAY
2001

U.S. Food and Drug Administration
Dockets management Branch
5630 Fishers Lane Room 1061 HFA-305
Rockville
maryland 20852

20857/0001